about
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialSMAD2, SMAD3 and SMAD4 mutations in colorectal cancer31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part onePhase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal CancerCirculating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerA phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.Wiki-based clinical practice guidelines for the management of adult onset sarcoma: a new paradigm in sarcoma evidence.A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer PatientsA First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial MinicellsCirculating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancerICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancerImpact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutationDNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon CancerDifferent APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis.Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians.Response assessment in gastrointestinal stromal tumor.Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.An Australasian perspective on sarcoma research, translational biology and clinical trials: the Australasian Sarcoma Study Group (ASSG).Controversies in the management of gastrointestinal stromal tumors.Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria.Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma.Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.
P50
Q28268831-78BC46E7-7DE3-4E0F-B2CD-CB3B4BE5554BQ28278952-ED0787DE-4B13-40A2-8EAB-39BFF76381ACQ28553703-E340EF98-F592-4221-91B4-86E85549BA1CQ33400785-BCFFAA44-197F-4DDD-AFEE-D336ACC6CADAQ33813216-4F45BC52-E6B0-468B-BB05-0CCA16308CC9Q33972047-C5EE5827-77A2-431C-A7A0-198F1F2E394AQ34062558-A25C0285-840E-4F97-8A8E-050827DCD624Q34533164-7A086293-86FD-40B0-8F02-CD2B2225473CQ34578099-26F5A6F5-9E9D-48BC-9A7B-7A59B1DC0D80Q34628085-73C2B3DC-DC20-41D0-B0D0-999B274BB8B6Q34687036-AC289A74-6E1C-4C85-9A00-B88C415F3BFAQ34976887-A9FA851F-6FA1-41CF-8140-FDF717DA3B54Q35133820-235CF4CB-9DAD-471E-B861-E0D6C32F01BFQ35187723-30E44B09-F67E-4366-95D0-A9F76A647642Q35620994-5DBAF83A-201C-4F04-9124-898EEF978A1AQ35867171-BAED29B1-49AA-474D-8B63-D3482CC1D4E4Q35879064-6C476CED-B5EB-4A6F-B5F6-60AD9A021E78Q36035723-7ECF272E-2A1E-4184-803F-D975DBCFEA21Q36081402-7D4780F9-53B5-47F5-800E-3CE535B566C9Q36551145-72B18C1D-E846-47FF-9FAB-72CF1B2BF6E2Q37020817-64B4AE31-0EDF-483B-8D28-5C6B8C9ECF1AQ37100057-ADA1B06C-A000-40C6-8208-9CE7F1F8CB8DQ37209240-BEE6DD2E-E052-41B9-9951-AB2CE3D938D1Q37222191-3B273C6E-D2AF-4F98-A2CD-5B5C1FA910D0Q37699880-49B98DA4-2BFD-44F2-B442-CF2C893F323EQ37801348-330A19B6-7587-4648-90F3-5AE62A97A5E6Q37988591-0CBB2FBD-0644-40C5-8A93-DD7D58593D3DQ37999442-E1DFFE53-E941-420F-BCB5-58AA3C898580Q38023976-17A9C9B6-DE8C-4807-826F-82BCE50494E6Q38110084-EA8A420D-A94A-4EFA-9827-4BD4A382281AQ38174736-584F294A-93D2-4B56-B9AD-4869A49166B0Q38199797-91B11FD8-9813-41E9-ADB3-AF526749A1DEQ38239612-5EA36150-09BE-4EFA-A2A2-83E5D2105BEEQ38391778-9A679246-C31C-4B8B-B194-D57379FDD613Q38405130-E6D7E41E-15BB-4DD0-9116-33E1160B87B4Q38565991-49DC6D03-A92C-4852-B2AF-A270ED41CFACQ38995724-5D40AA28-8260-4694-B9B1-98CD8FF1BECDQ39043653-4B56E750-EFCF-4219-968B-27DBA085C7B1Q39203827-3FDF85DB-D990-46E4-A0DB-5B3610500718Q39685279-2D9733F8-2A00-4402-A5B1-24DD2B07F6F6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jayesh Desai
@ast
Jayesh Desai
@en
Jayesh Desai
@es
Jayesh Desai
@nl
type
label
Jayesh Desai
@ast
Jayesh Desai
@en
Jayesh Desai
@es
Jayesh Desai
@nl
prefLabel
Jayesh Desai
@ast
Jayesh Desai
@en
Jayesh Desai
@es
Jayesh Desai
@nl
P108
P106
P1153
8591952600
P31
P496
0000-0003-4246-9344